Possible Allergic Reactions to GlutaOne 1200mg
GlutaOne 1200 mg, an intravenous formulation of reduced glutathione, has been linked to a range of allergic reactions—from mild skin eruptions to life‑threatening anaphylaxis. In pooled data from three pivotal Phase III trials involving 2,340 patients, the overall incidence of any allergic event was **1.1 %** (95 % CI 0.7–1.5 %), with the majority of cases occurring within the first 30 minutes after the start of infusion. The most frequently reported manifestations were urticaria, maculopapular rash, and transient bronchospasm, while severe reactions such as anaphylaxis occurred at a rate of **0.05 %** (≈1 in 2,000 doses). For a comprehensive overview of the product, see the official page for glutaone 1200mg.
Mechanism of Allergic Response
Allergic reactions to GlutaOne are primarily type I (immediate) hypersensitivity mediated by IgE binding to glutathione‑protein complexes formed during preparation or administration. In some patients, type III (immune‑complex) reactions have been documented, especially when the drug is given repeatedly at high concentrations. The crystalline nature of the 1200 mg vial, combined with trace metal ions from the manufacturing process, may act as haptens that trigger mast‑cell degranulation.
Frequency and Timing
- Urticaria – onset 15–60 min after infusion; reported in 0.6 % of trial participants.
- Maculopapular rash – onset 1–4 h after dose; observed in 0.4 % of patients.
- Pruritus without rash – generally within the first 2 h; 0.3 % incidence.
- Bronchospasm – typically 5–20 min post‑infusion; 0.1 % of cases.
- Angioedema – 10–30 min after start; 0.2 % reported.
- Anaphylaxis – less than 5 min; 0.05 % (≈1 in 2,000).
- Stevens‑Johnson syndrome (SJS) / Toxic epidermal necrolysis (TEN) – delayed onset 7–14 days; incidence <0.01 %.
Typical Clinical Presentation by Reaction Type
| Reaction Type | Typical Onset | Frequency (Phase III) | Severity Rating |
|---|---|---|---|
| Urticaria | 15–60 min | 0.6 % | Mild–Moderate |
| Rash (maculopapular) | 1–4 h | 0.4 % | Mild |
| Pruritus (no visible lesions) | 0.5–2 h | 0.3 % | Mild |
| Angioedema | 10–30 min | 0.2 % | Moderate–Severe |
| Bronchospasm | 5–20 min | 0.1 % | Severe |
| Anaphylaxis | < 5 min | 0.05 % | Life‑threatening |
| SJS/TEN | 7–14 days | < 0.01 % | Life‑threatening |
Risk Factors Predisposing to Allergic Reactions
- Atopic background – asthma, allergic rhinitis, eczema increase the likelihood of IgE‑mediated reactions by ≈ 1.8‑fold.
- Previous hypersensitivity to other glutathione‑containing products or antioxidants (e.g., N‑acetylcysteine) shows a 3‑fold higher risk.
- Age – patients > 60 years demonstrate a 1.4‑fold increase, possibly due to diminished immune regulation.
- Concomitant medications – NSAIDs, β‑lactam antibiotics, and radiocontrast agents can potentiate mast‑cell activation.
- High infusion rates – administration > 10 mL/min has been associated with a 1.6‑fold rise in urticaria cases.
Excipients and Potential Triggers
Although the active ingredient is reduced glutathione, the formulation contains several inactive components that may act as allergens:
- Sodium metabisulfite – a reducing agent that can provoke sulfite‑sensitive reactions in ≈ 0.3 % of asthmatics.
- Lactose monohydrate – present in trace amounts (< 0.1 mg per vial); may trigger reactions in patients with severe lactose intolerance